We have redefined the standard of excellence

Meet FIECON Strategic Council

Dr Susan Suponcic
US commercialisation expert 

Dr Susan Suponcic brings a wealth of US and Global pricing and market access commercialisation expertise. Her vast experience across US pharmaceutical companies and global consultancies will be leveraged to provide FIECON clients’ access to specific US launch and commercialisation expertise.
Strategic & tactical highlights:
  • US Congressional and patient advocacy recognition of innovation and corporate responsibility in developing, pricing and launching HIV therapies.
  • Corporate benchmarks for speed of access at or above (>20%) target prices for global launches in > 20 markets invirology, oncology and immunology.
  • Incremental US revenues for in-market products of over $3 billion in less than 5 years.
  • Increase in US average selling price of> 40% while increasing sales volume by >20% for consulting clients.

Dawn Lee
Associate Professor of Health Economics and Health Policy 

Dawn Lee is a renowned figure in the field of health technology assessment, bringing a wealth of global experience that spans over 30 countries. As a collaborator with Peninsula Technology Assessment Group (PenTAG), Dawn lends her expertise to appraise the clinical and cost-effectiveness of new drugs, offering critical guidance to the National Institute for Health and Care Excellence (NICE) in the UK. Her distinguished career includes a tenure as the Chief Scientific Officer at Lumanity (formerly known as BresMed), where she solidified her reputation as a proficient health economic modeller. Dawn's impressive portfolio boasts more than 50 UK Health Technology Assessment submissions, underscoring her significant contribution to the advancement of healthcare standards and drug efficacy evaluation.
Contributions to NICE:
  • Member of the Interventional Procedures Advisory Committee (IPAC)
  • Member of the R for HTA group
  • Represented manufacturers at around 30 HTA Committee meetings
  • Involved in groundbreaking submissions to NICE as both manufacturer and EAG, including:
    • NICE's first pathways pilot (ID6186)
    • One of NICE's Early Value Assessment pilots (HTE8)
    • First-ever immune-oncology submission (TA268)
    • First-ever PD-1 submission (TA384)
    • Several subsequent pioneering efforts
    • The fastest delivering proportionate approach pilot (TA868)
  • Played a pivotal role in the acceptance of the first ITC by G-BA

Eric Low, OBE
Patient advocate 

Eric Low is a healthcare professional who has demonstrated an unwavering commitment to enhancing patient outcomes and ensuring that patients remain central to all decision-making processes. His work is driven by the ultimate goal of focusing on the prevention and curability of cancer and rare diseases, reflecting a deep dedication to medical advancement in these areas. Eric's efforts are consistently directed toward strategies and solutions that aim to significantly improve the quality of life for patients, embodying a patient-first philosophy in his approach to healthcare.
Achievements:
  • Building collaborative research initiatives
  • Uniting patient coalitions for collective action
  • Devising effective market access strategies
  • Influencing policy changes in the healthcare sector.
  • Delivering innovative solutions to complex challenges in healthcare.
Patient advocacy and leadership roles:
  • Serving on boards, honorary positions, and advisory capacities
  • Generously providing pro bono advice to medical and health-focused charities
Recognition:
  • Honoured with an OBE (Order of the British Empire) in 2012 for outstanding contributionsto charity in the Queen's Birthday Honours list.
Together, we'll revolutionise your approach

Ready to transform your potential?

Book a meeting